EP4125960A4 - Use of stem cells for treatment of excessive inflammation - Google Patents

Use of stem cells for treatment of excessive inflammation

Info

Publication number
EP4125960A4
EP4125960A4 EP21781682.6A EP21781682A EP4125960A4 EP 4125960 A4 EP4125960 A4 EP 4125960A4 EP 21781682 A EP21781682 A EP 21781682A EP 4125960 A4 EP4125960 A4 EP 4125960A4
Authority
EP
European Patent Office
Prior art keywords
treatment
stem cells
excessive inflammation
inflammation
excessive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21781682.6A
Other languages
German (de)
French (fr)
Other versions
EP4125960A1 (en
Inventor
Mark Andreas Kluth
Markus H. Frank
Christoph Ganss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheacell & Co Kg GmbH
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of EP4125960A1 publication Critical patent/EP4125960A1/en
Publication of EP4125960A4 publication Critical patent/EP4125960A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21781682.6A 2020-03-30 2021-03-30 Use of stem cells for treatment of excessive inflammation Pending EP4125960A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063002274P 2020-03-30 2020-03-30
PCT/US2021/024947 WO2021202570A1 (en) 2020-03-30 2021-03-30 Use of stem cells for treatment of excessive inflammation

Publications (2)

Publication Number Publication Date
EP4125960A1 EP4125960A1 (en) 2023-02-08
EP4125960A4 true EP4125960A4 (en) 2024-04-03

Family

ID=77927437

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21781682.6A Pending EP4125960A4 (en) 2020-03-30 2021-03-30 Use of stem cells for treatment of excessive inflammation

Country Status (3)

Country Link
US (1) US20230148432A1 (en)
EP (1) EP4125960A4 (en)
WO (1) WO2021202570A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143139A1 (en) * 2006-05-31 2007-12-13 The Brigham And Women's Hospital, Inc. Abcb5 positive mesenchymal stem cells as immunomodulators
WO2014130518A1 (en) * 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
WO2016086020A1 (en) * 2014-11-24 2016-06-02 Cytostormrx Llc Encapsulated stem cells for the treatment of inflammatory disease
US20170312317A1 (en) * 1998-03-27 2017-11-02 Northern Therapeutics Inc. Cell-based therapy for the pulmonary system
EP3946389A1 (en) * 2019-03-28 2022-02-09 Children's Medical Center Corporation Highly functional manufactured abcb5+ mesenchymal stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014262590B2 (en) * 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
WO2018185584A1 (en) * 2017-04-05 2018-10-11 Pluristem Ltd. Methods and compositions for treating acute lung injury and respiratory distress syndrome
ES2951396T3 (en) * 2019-10-18 2023-10-20 Amniotics Ab Procedures and devices for obtaining amniotic mesenchymal stem cells from amniotic fluid and its derived cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170312317A1 (en) * 1998-03-27 2017-11-02 Northern Therapeutics Inc. Cell-based therapy for the pulmonary system
WO2007143139A1 (en) * 2006-05-31 2007-12-13 The Brigham And Women's Hospital, Inc. Abcb5 positive mesenchymal stem cells as immunomodulators
WO2014130518A1 (en) * 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
WO2016086020A1 (en) * 2014-11-24 2016-06-02 Cytostormrx Llc Encapsulated stem cells for the treatment of inflammatory disease
EP3946389A1 (en) * 2019-03-28 2022-02-09 Children's Medical Center Corporation Highly functional manufactured abcb5+ mesenchymal stem cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
L. A. ORTIZ ET AL: "Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 104, no. 26, 26 June 2007 (2007-06-26), pages 11002 - 11007, XP055317073, ISSN: 0027-8424, DOI: 10.1073/pnas.0704421104 *
See also references of WO2021202570A1 *
TOBIAS SCHATTON: "ABCB5 Identifies Immunoregulatory Dermal Cells", CELL REPORTS, vol. 12, no. 10, 1 September 2015 (2015-09-01), US, pages 1564 - 1574, XP055327957, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2015.08.010 *
ZIKUAN LENG ET AL: "Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia", AGING AND DISEASE, vol. 11, no. 2, 1 January 2020 (2020-01-01), US, pages 216, XP055742483, ISSN: 2152-5250, DOI: 10.14336/AD.2020.0228 *

Also Published As

Publication number Publication date
EP4125960A1 (en) 2023-02-08
US20230148432A1 (en) 2023-05-11
WO2021202570A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
EP4132507A4 (en) Methods of treatment of coronavirus-induced inflammation conditions
EP3947647A4 (en) Methods for production of car-nk cells and use thereof
EP4142882A4 (en) Methods of treating abnormal cell growth
EP4003299A4 (en) Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
EP3952881A4 (en) Compositions and methods for the treatment of contact lens discomfort
EP4041255A4 (en) Modified stem cells and methods of use thereof
EP4096703A4 (en) Therapeutic uses of tirzepatide
EP4003246A4 (en) Compositions and methods for treatment of presbyopia
EP4041252A4 (en) Development of embryonic-like tissue from stem cells
EP4125960A4 (en) Use of stem cells for treatment of excessive inflammation
EP4028120A4 (en) Selective laser stimulation of corneal stem cells
EP3972556A4 (en) Use of csa compounds to stimulate stem cells and hair growth
EP3362044A4 (en) Treatment for infection composed of menstrual stem cells
CA3135658A1 (en) Mesenchymal stem cells for treatment of skin disorders and skin problems
EP3801590A4 (en) Compositions and methods for treatment of psoriasis
EP4103173A4 (en) Compositions for treatment of psoriasis of the scalp
EP4099997A4 (en) Methods and compositions for treatment of diseases
EP4100127A4 (en) Methods for the treatment of scleroderma and related conditions
EP3774849A4 (en) Treatment of inflammation
EP4110353A4 (en) Use of early apoptotic cells for treating covid-19
EP3865572A4 (en) Medium for growth of neuronal stem cells
AU2022421049A1 (en) Compositions for treatment of inflammation
AU2022405685A1 (en) Treatment of nociceptive pain
AU2022417496A1 (en) Use of tawox for improving regeneration of plant cells
AU2021900862A0 (en) Treatment of Inflammatory Diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088482

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20240305

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/02 20060101ALI20240228BHEP

Ipc: A61P 31/14 20060101ALI20240228BHEP

Ipc: A61P 29/00 20060101ALI20240228BHEP

Ipc: A61K 35/28 20150101AFI20240228BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RHEACELL GMBH & CO. KG

Owner name: CHILDREN'S MEDICAL CENTER CORPORATION